Evidence map›Paper›PMID 37353711›Full record

ArticleLeukemia2023

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study.

Kirsi Manz, Jeanette Bahr, Till Ittermann, Konstanze Döhner, Steffen Koschmieder, Tim H Brümmendorf, Martin Griesshammer, Matthias Nauck, Henry Völzke, Florian H Heidel

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kirsi ManzInstitut für Community Medicine - Abteilung Versorgungsepidemiologie und Community Health, Universitätsmedizin Greifswald, Greifswald, Germany.ORCID 0000-0002-7740-4076
Jeanette BahrInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Till IttermannInstitut für Community Medicine - Abteilung SHIP-KEF, Universitätsmedizin Greifswald, Greifswald, Germany.
Konstanze DöhnerGerman MPN Study Group, GSG-MPN, Germany.
Steffen KoschmiederGerman MPN Study Group, GSG-MPN, Germany.ORCID 0000-0002-1011-8171
Tim H BrümmendorfGerman MPN Study Group, GSG-MPN, Germany.
Martin GriesshammerGerman MPN Study Group, GSG-MPN, Germany.
Matthias NauckInstitute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
Henry VölzkeInstitut für Community Medicine - Abteilung SHIP-KEF, Universitätsmedizin Greifswald, Greifswald, Germany.
Florian H HeidelInnere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany. florian.heidel@uni-greifswald.de.ORCID 0000-0003-2438-1955

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myeloproliferative DisordersNeoplasmsThromboembolismHumansPrognosisRetrospective StudiesRisk Factors

Identifiers

PMID37353711
PMCPMC10400416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.